IAG
WHWK

Investmark Advisory Group’s Whitehawk Therapeutics WHWK Stock Holding History

Investmark Advisory Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$2K – 373
2021
Q4 		$2K Buy
+100
New +$2.51K ﹤0.01% 360

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Investmark Advisory Group's WHWK Position: Q1 2022 in Review

Investmark Advisory Group sold out of Whitehawk Therapeutics (WHWK) in Q1 2022, closing a stake of 100 shares — an estimated $2K sold.

Investmark Advisory Group first reported a position in WHWK in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 55 funds tracked by Wall St. Rank hold WHWK as of Q1 2022.

  • Investmark Advisory Group reported no remaining Whitehawk Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Investmark Advisory Group sold 100 Whitehawk Therapeutics shares in Q1 2022, an estimated $2K.
  • Investmark Advisory Group first reported a position in Whitehawk Therapeutics in Q4 2021 and held it in 1 quarter.
  • Investmark Advisory Group's Whitehawk Therapeutics position peaked at $2K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2022.

Based on Investmark Advisory Group's 13F filing for Q1 2022, filed 3 May 2022.